{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shen YG"],"funding":["Shanghai Science and Technology Commission's Explorer Program","the National Key R&D Program of China","the National Natural Science Foundation of China","the Clinical Research Plan of Shanghai Hospital Development Center"],"pagination":["137"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690028"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements constitutes a distinct clinicopathological entity characterized by aggressive behavior, inherent resistance to conventional immunochemotherapy, and suboptimal clinical outcomes. Within our cohort, MYC/BCL2 rearrangements defined double-hit lymphoma (DHL), MYC/BCL6 as DHL-BCL6, and concurrent MYC/BCL2/BCL6 as triple-hit lymphoma (THL). Here, we delineated the clinical characteristics and genetic aberrations of 112 DHL/THL patients to investigate the factors influencing lymphoma relapse and optimize treatment strategies. Compared to 80 DHL-BCL6 patients, DHL/THL manifested distinct features, including an increased prevalence of the germinal center B-cell-like subtype and co-expression of MYC/BCL2, and demonstrated signif"],"journal":["Molecular biomedicine"],"pubmed_title":["Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study."],"pmcid":["PMC12690028"],"funding_grant_id":["82170178","82570246","2022YFC2502600","25TS1404000","SHDC2020CR1032B","82130004","82200201","2023YFC3605704"],"pubmed_authors":["Ji MM","Wang XB","Shi Q","Huang L","Zhao WL","Wei XL","Shen YG","Liang AB","Zhu ZM","Wang L","Cheng S","Liu Y","Bai O","Xu B","Fan L","Wang X","Tang W","Zhou H","Zheng Z","Huang HH","Shi WY","Yi HM","Chen SY","Li F","Xu PP","Dong LH","Yang SM","Liu TB","Shi KQ","Tian YY"],"additional_accession":[]},"is_claimable":false,"name":"Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.","description":"High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements constitutes a distinct clinicopathological entity characterized by aggressive behavior, inherent resistance to conventional immunochemotherapy, and suboptimal clinical outcomes. Within our cohort, MYC/BCL2 rearrangements defined double-hit lymphoma (DHL), MYC/BCL6 as DHL-BCL6, and concurrent MYC/BCL2/BCL6 as triple-hit lymphoma (THL). Here, we delineated the clinical characteristics and genetic aberrations of 112 DHL/THL patients to investigate the factors influencing lymphoma relapse and optimize treatment strategies. Compared to 80 DHL-BCL6 patients, DHL/THL manifested distinct features, including an increased prevalence of the germinal center B-cell-like subtype and co-expression of MYC/BCL2, and demonstrated signif","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T00:07:59.65Z","creation":"2026-05-23T03:13:40.461Z"},"accession":"S-EPMC12690028","cross_references":{"pubmed":["41364305"],"doi":["10.1186/s43556-025-00346-8"]}}